



## Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

November 26, 2019

SEATTLE, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design *de novo* protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Piper Jaffray 31<sup>st</sup> Annual Healthcare Conference on Thursday, December 5, 2019 at 2:50 p.m. EST in New York.

A live webcast of the presentation will be available from the investors section of the Neoleukin website at <http://investor.neoleukin.com/events>. An archived replay of the presentation will also be available on the company website for at least 30 days following the event.

### About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation, and autoimmunity using *de novo* protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. For more information, please visit the Neoleukin website: [www.neoleukin.com](http://www.neoleukin.com).

### Cautionary Note on Forward-Looking Statements

Certain of the statements made in this press release are forward looking, including those relating to evaluation of our pipeline and strategic options, potential timing of preclinical data, the sufficiency of our cash resources and other statements containing the words "anticipate," "believe," "expect," "may," "plan," "project," "potential," "will," "would," "could," "continue," and similar expressions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: clinical drug development is a lengthy and expensive process with an uncertain outcome; our ability to identify or acquire additional clinical candidates, our ability to obtain and maintain regulatory approval for any future product candidates and the potential safety, efficacy or clinical utility of or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Neoleukin is contained in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Neoleukin disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### Contacts:

#### Media

Julie Rathbun  
206-769-9219  
[jrathbun@neoleukin.com](mailto:jrathbun@neoleukin.com)

#### Investors

Solebury Trout  
Brian Korb  
646-378-2923  
[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)



Source: Neoleukin Therapeutics, Inc.